InSysBio, one of the world’s pioneers of Quantitative Systems Pharmacology (QSP) modeling, held its 14th Annual Internal Scientific Meeting on February 11-13, 2024. The Meeting was organized for the first time after the pandemic and InSysBio’s Headquarters relocation to Cyprus.
InSysBio’s teams presented the results of 2023 performance and discussed plans and ideas for the future development. Oleg Demin, Chief Scientific Advisor and co-founder of InSysBio, opened the Meeting by the overview of InSysBio’s twenty years of operation. During this period InSysBio performed a diverse range of QSP modeling projects in collaboration with pharmaceutical giants. Moreover, InSysBio developed its own fully-fledged QSP infrastructure that includes QSP databases (CYTOCON DB, fIVE DB), softs (Heta) and tools (IRT). All of them were significantly enhanced throughout the year and further update is underway. In frames of QSP models and platforms development the company experienced in a variety of therapeutic areas and currently mainly focuses on oncology, immunology, immuno-oncology, rare diseases and neurodegenerative diseases. In 2023 InSysBio participated in four conferences, namely, PAGE 2023, World Bispecific Summit 2023, SITC 2023 and ACoP14.
The Meeting was closed up by a heated discussion of AI and ML in QSP modeling. Besides, the perspective outlook shows that the company has intention towards constant growth. This year InSysBio is going to present its results at ASCPT 2024, PAGE 2024, ACoP15.
About InSysBio
InSysBio is a group of Quantitative Systems Pharmacology (QSP) companies located in Limassol, Cyprus (INSYSBIO CY Ltd) and Edinburgh, UK (INSYSBIO UK LIMITED). InSysBio was founded in 2004 and has an extensive track record of helping pharmaceutical companies to make right decisions on the critical stages of drug research and development by application of QSP modeling. InSysBio’s innovative QSP approach has already become a part of the drug development process implemented by our strategic partners: there are more than 100 completed projects in collaboration with leaders of pharmaceutical industry. For more information about InSysBio, its solutions and services, visit www.insysbio.com
| ← | March 2025 | → | ||||
| Mo | Tu | We | Th | Fr | Sa | Su |
|---|---|---|---|---|---|---|
|
1
|
2
| |||||
|
3
|
4
|
5
|
6
|
7
|
8
|
9
|
|
10
|
11
|
12
|
13
|
14
|
15
|
16
|
|
17
|
18
|
19
1.
19 Mar 2025 15:40
The project aims at mechanistic modeling of antibodies to predict pharmacokinetics and target occupancy in cerebrospinal fluid
InSysBio, one of the world’s pioneers of Quantitative Systems Pharmacology (QSP) modeling, announces its collaboration with discoveric bio alpha, a biotechnology company taking next generation antibody technologies into Alzheimer’s Disease
|
20
|
21
|
22
|
23
|
|
24
|
25
|
26
1.
26 Mar 2025 00:12
InSysBio to participate in AACR 2025
InSysBio announces its participation in AACR Annual Meeting 2025 which is to be held from April 25-30, 2025, at McCormick Place Convention Center, Chicago, Illinois, USA. InSysBio team is going to present their QSP modeling services and software to optimize drug development at Booth #4845 and 3 posters in frames of the Meeting
|
27
|
28
|
29
|
30
|
|
31
| ||||||
Thank you for your message! We will get back to you shortly.
